Empagliflozin and metformin hydrochloride

Synjardy

Mechanism of action: SGLT2 inhibitor + biguanide (fixed-dose combination)
In plain language: Combines two diabetes medicines in one tablet: empagliflozin, which makes the kidneys pass extra sugar out in the urine, and metformin, which tells the liver to release less sugar into the blood and helps the body use insulin more effectively.
How it works: SYNJARDY combines empagliflozin, an SGLT2 inhibitor, and metformin hydrochloride, a biguanide. Per the FDA label, empagliflozin inhibits SGLT2, the transporter responsible for most glucose reabsorption from the kidney's filtrate back into the bloodstream; blocking it lowers the renal threshold for glucose and increases urinary glucose excretion, independent of insulin. Metformin acts through a separate pathway, decreasing hepatic glucose production and improving peripheral insulin sensitivity. Because the two mechanisms don't overlap -- one acting on the kidney, the other on the liver and muscle -- combining them controls blood sugar more effectively than either alone.
Therapeutic applications: SYNJARDY is FDA-indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Because it contains metformin, SYNJARDY carries a boxed warning for lactic acidosis, a rare but serious risk of metformin-containing products.
Class: Fixed-dose combination
Therapeutic area: Metabolic / Diabetes
Source: FDA label (DailyMed) ↗

Contains